Sera Prognostics Inc is a health diagnostic company. It is a women's health company utilizing the proprietary proteomics and bioinformatics platform, and data resources to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$1.93 – $1.98
Volume12,437
Market cap$77M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$77.15M
Price / earnings
—
Price / book
1.47×
Price / sales
803.68×
EV / sales
762.16×
EV / EBITDA
-2.01×
Profitability
Earnings per share
-$0.84
Return on assets
-41.85%
Return on equity
-63.83%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
1.88×
Quick ratio
1.88×
Cash ratio
0.16×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$28.99M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for SERA, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$42K
$30K
$14K
$10K
$16K
$17K
$38K
$24K
Cost of revenue
$61K
$50K
$42K
$42K
$41K
$41K
$40K
$32K
Gross profit
-$19K
-$20K
-$28K
-$32K
-$25K
-$24K
-$2K
-$8K
Selling, general and administrative
$6.15M
$6.49M
$6.3M
$5.71M
$5.67M
$5.96M
$5.91M
$6.28M
Research and development
$2.72M
$3.49M
$3.03M
$3.22M
$3.28M
$3.34M
$3.33M
$3.14M
Total operating expenses
$8.87M
$9.98M
$9.33M
$8.92M
$8.96M
$9.3M
$9.25M
$9.42M
Operating income
-$8.89M
-$10M
-$9.36M
-$8.95M
-$8.98M
-$9.32M
-$9.25M
-$9.42M
Interest expense
-$2K
-$2K
-$2K
-$1K
-$2K
-$2K
-$4K
-$6K
Income before taxes
-$8.05M
-$9.14M
-$8.4M
-$7.88M
-$7.81M
-$8.05M
-$8.19M
-$8.58M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$8.05M
-$9.14M
-$8.4M
-$7.88M
-$7.81M
-$8.05M
-$8.19M
-$8.58M
Net income attributable to common shareholders
-$8.05M
-$9.14M
-$8.4M
-$7.88M
-$7.81M
-$8.05M
-$8.19M
-$8.58M
EBITDA
-$8.7M
-$9.81M
-$9.17M
-$8.71M
-$8.74M
-$9.08M
-$9.03M
-$9.21M
Basic earnings per share
-$0.16
-$0.18
-$0.17
-$0.16
-$0.16
-$0.16
-$0.20
-$0.25
Diluted earnings per share
-$0.16
-$0.18
-$0.17
-$0.16
-$0.16
-$0.16
-$0.20
-$0.25
Recent news
Company coverage with links to the original publishers.
Sera Prognostics reported a fivefold increase in test volume for its PreTRM blood test from Q1 to Q3 2026, driven by expanding Medicaid coverage in Florida and Illinois and growing physician adoption. The company expects flat or declining operating expenses in 2027 while expanding its commercial team, with $72.8 million in cash funding operations through fiscal 2029. Long-term growth depends on securing clinical guideline inclusion and expanding state Medicaid coverage.
Sera Prognostics reported a quarterly loss of $0.16 per share, missing consensus estimates of $0.14, with revenues of $0.04 million falling 47.5% short of expectations. The stock has declined 34.6% year-to-date versus the S&P 500's 10.6% gain. The company holds a Zacks Rank #3 (Hold) rating and is expected to perform in line with the market.